MADRIGAL PHARMACEUTICALS, INC. Revenue, Remaining Performance Obligation, Percentage
MADRIGAL PHARMACEUTICALS, INC. (MDGL) had Revenue, Remaining Performance Obligation, Percentage of 2.00% as of 2024-06-30, per its 10-Q filed 2024-08-07.
Discontinued › Notes
us-gaap:RevenueRemainingPerformanceObligationPercentage · last filed 2024-08-07
- 2024-06-30: Revenue, Remaining Performance Obligation, Percentage 2.00%.
| Period end | Revenue, Remaining Performance Obligation, Percentage |
|---|---|
| 2024-06-30 | 2.00% 10-Q · filed 2024-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |